Insights

Type

Select all that apply

Topic

Select all that apply

icons/content-types/video webinar

Presented by Brian Haney, Ph.D., Director of Technical Operations, Curia Iain MacGilp, Ph.D., Director, GMP Production, Curia Listen in as our experts discuss: The basics of handling HPAPI's safely in GMP production settings The trad...

icons/content-types/white paper white paper

The COVID-19 pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. The U.S. Food and Drug Administration (FDA) repor...

icons/content-types/video webinar

Presenters: Ankit Agrawal, Senior Director, Commercial Strategy, Curia Anish Parikh, Vice President, Drug Product Sales & Marketing, Curia Listen in as our experts discuss: The shortage of sterile manufacturing capacity within CDMOs given...

icons/content-types/video webinar

Presenters: Peter Talbiersky, Ph.D., Manager of Fine Chemicals Sales, Curia Listen in as our experts discuss: The importance of a green and versatile condensation reagent Safe alternative for commonly used condensation reagents like dicyclohe...

icons/content-types/video webinar

Presenters: Iain MacGilp, Ph.D., Director, GMP Production, Curia Amber McFarlane, Head of Formulation Development, Curia Listen in as our experts discuss: The importance of an integrated formulation development and clinical supply function th...

icons/content-types/article article

Though synthetic biology may be regarded as a new or emerging field of science, the concept of applying biological systems to improve chemical synthesis goes back hundreds — arguably, thousands — of years. From the earliest fermentation processes...

icons/content-types/article article

As part of our deep commitment to diversity and inclusion in the workplace, Curia (formerly AMRI) is very proud to be participating in the two-year Mansfield Rule: Legal Department Edition (MRLD) initiative.

icons/content-types/video webinar

In vitro biochemical assays make possible the high throughput screening (HTS) of large compound libraries. A successful HTS campaign is typically viewed as one that identifies large numbers of diverse chemical series hits as potential starting points...

icons/content-types/article article

CDMOs that routinely handle highly potent compounds must raise the bar for containment, safety, and industrial hygiene. Diverse capabilities across chemistries, purification technologies, and analytical techniques — combined with the ability to sup...

icons/content-types/article article

It is no coincidence that the booms in prefilled syringes (PFS) and biologic medicines are happening at the same time – the two are intrinsically linked. Innovative biologic medicines demand innovative delivery systems to match, and as the utility...